Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve pharminent May 26, 2026
Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study pharminent May 26, 2026
Regulatory AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs pharminent May 18, 2026
Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026
Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial pharminent May 12, 2026
Commercial Pfizer protects $6.4bn heart disease blockbuster from generics, for now pharminent April 29, 2026
Clinical Data Cardiometabolic trials: Using expertise to turn complexity into robust results pharminent April 24, 2026
Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH pharminent April 2, 2026
Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D pharminent April 1, 2026
Clinical Data ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose pharminent April 1, 2026
Clinical Data ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit pharminent April 1, 2026
Clinical Data Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout pharminent March 30, 2026
M&A / Deals Immutrin raises $87M to advance drug for progressive heart disease pharminent March 24, 2026
